Video

Application of Payment Reform Models in Oncology

ASCO has proposed new payment approaches that have some flexibility, notes Jeffrey C. Ward, MD. One model, he explains, is based on a fee-for-service system, but adds patient management fees and accountability for lowering the cost of care. It has not yet been determined whether unnecessary utilization is reduced with this model.

A variation on this model incorporates a monthly bundled payment that allows for flexibility in how the care is provided. This allows practices to innovate and add other care providers to the team, such as palliative care clinicians or nurse practitioners. It also allows them to practice at the top of their licenses, says Ward.

The final model is based on an all-inclusive bundle, which can include medications or exclude them. Many practices will never be able to manage this level of risk, states Ward. Although the Centers for Medicare & Medicaid Services’s Oncology Care Model may have benefits, adds Ward, it is important to test other models as well.

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.